Your new experience awaits. Try the new design now and help us make it even better

CASE REPORT article

Front. Oncol.

Sec. Gastrointestinal Cancers: Gastric and Esophageal Cancers

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1576874

Gastric metastasis arising from invasive ductal and mucinous carcinoma of the breast: A case report and literature review

Provisionally accepted
Zhidong  LyuZhidong Lyu*Jie  FeiJie FeiLongxiao  ZhangLongxiao ZhangYinbo  LiuYinbo Liu*
  • Qingdao University, Qingdao, Shandong Province, China

The final, formatted version of the article will be published soon.

Gastric metastasis of breast cancer is rare, and clinical data on its treatment and prognosis are limited at present. Herein, we report a case of gastric metastasis arising from invasive ductal and mucinous carcinoma of the breast and review the literature.A 51-year-old woman was diagnosed with infiltrating and mucinous carcinoma of the right breast accompanied by ipsilateral axillary lymph node and subclavian lymph node metastases. The molecular subtype was luminal A, and the clinical stage was T4bN3M0. The patient first received 5 cycles of neoadjuvant chemotherapy, and the treatment efficacy was stable. After 3 months of treatment with abemaciclib combined with exemestane, the tumors did not significantly reduce in size. The patient underwent surgery on February 23, 2023. The postoperative pathological examination revealed Miller Payne system grade 3 (G3). Cancer metastasis (14/20) was observed in the axillary lymph nodes, and the immunohistochemical results were as follows: ER (++, 90%), PR (+, 2%), HER-2 (3+), and Ki-67 (20%). The adjuvant therapy used was exemestane combined with trastuzumab and pertuzumab. Gastric metastasis was observed 10 months after surgery. The pathological examination revealed focal atypical cell nests with disordered arrangements, indicating malignant lesions (cancer).The immunohistochemical results were as follows: GATA3 (+), ER (++, 90%), PR (-), and HER-2 (1+). In the late stage, first-line treatment with dalpiciclib and fulvestrant was administered, and liver metastasis occurred 10 months thereafter. T-DXd treatment was subsequently administered, and the patient is currently undergoing clinical follow-up. This case highlights the possibility of gastric metastasis when gastrointestinal symptoms occur in patients with a history of breast cancer.

Keywords: breast cancer, Gastric metastasis, HER-2, CDK4/6 inhibitor, case report

Received: 29 May 2025; Accepted: 31 Jul 2025.

Copyright: © 2025 Lyu, Fei, Zhang and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Zhidong Lyu, Qingdao University, Qingdao, 266071, Shandong Province, China
Yinbo Liu, Qingdao University, Qingdao, 266071, Shandong Province, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.